Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK.
HIV
HR-HPV
cervical cancer screening
self-sampling
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
12
01
2022
received:
09
09
2021
accepted:
16
02
2022
pubmed:
5
3
2022
medline:
15
3
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
Current UK guidelines for cervical cancer screening are based on the assumption that most women living with HIV (WLWH) are also high-risk (HR) human papillomavirus (HPV)-positive. We aimed to provide data on prevalence of HR-HPV in WLWH in the UK and to assess feasibility and acceptability of HR-HPV self-sampling in this group. Women living with HIV attending six HIV services in London/south of England, with no history of cervical cancer, were enrolled. Participants self-collected a vaginal swab for the detection of HR-HPV, completed a survey about sexual/gynaecological history, attitudes towards annual screening and perception of HR-HPV self-sampling, and were asked to have their annual cervical smear. In all, 67 women were included: 86.5% were of black ethnicity, the median (range) age was 47 (24-60) years, median CD4 T-cell count was 683 cells/µL [interquartile range (IQR): 527-910], and 95.4% had viral load ≤ 50 copies/mL. All performed the vaginal swab. Eighteen (27%) had no cervical smear results; none of these women attended HIV services where this was routinely offered. No cervical samples were positive for HR-HPV. Three-quarters (75.8%) of participants reported adherence to annual screening, with only one woman (1.5%) attending irregularly. On visual analogue scales (from 0 to 100), median (IQR) acceptability and necessity of smear tests were 100 (75-100) and 100 (85-100), respectively. Our results suggest that the prevalence of HR-HPV in WLWH in the UK may be low. Self-sampling seems to be acceptable, suggesting, if validated, its potential role in supporting less frequent smear testing and improving screening uptake in WLWH.
Identifiants
pubmed: 35243750
doi: 10.1111/hiv.13257
pmc: PMC9314078
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-396Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Womens Health (Lond). 2021 Jan-Dec;17:17455065211017041
pubmed: 34096400
Br J Cancer. 2010 Jul 13;103(2):209-16
pubmed: 20628396
J Infect Dis. 2016 May 1;213(9):1455-61
pubmed: 26690345
Int J Cancer. 2016 Apr 1;138(7):1732-40
pubmed: 26537763
Int J Gynaecol Obstet. 2019 Dec;147(3):332-338
pubmed: 31489627
J Clin Virol. 2000 Oct;19(1-2):1-5
pubmed: 11091143
Int J STD AIDS. 2015 Nov;26(13):945-50
pubmed: 25505037
Prev Med. 2020 Mar;132:105953
pubmed: 31911163
BMC Cancer. 2017 Nov 9;17(1):734
pubmed: 29121873
Public Health. 2021 Jun;195:105-111
pubmed: 34082174
HIV Med. 2022 Apr;23(4):390-396
pubmed: 35243750
Int J Equity Health. 2020 Sep 11;19(1):160
pubmed: 32917224
Int J Gynecol Cancer. 2019 Apr 24;:
pubmed: 31018938
Oncol Lett. 2017 Dec;14(6):7629-7635
pubmed: 29344211
J Sex Transm Dis. 2013;2013:915169
pubmed: 26316967
BMJ Glob Health. 2019 May 14;4(3):e001351
pubmed: 31179035